Article

Travoprost approved as first-line IOP therapy

The FDA has approved once-daily travoprost ophthalmic solution 0.004% prescription eye drops (Travatan Z, Alcon Laboratories) as first-line treatment of elevated IOP associated with open-angle glaucoma or ocular hypertension

Huenenberg, Switzerland-The FDA has approved once-daily travoprost ophthalmic solution 0.004% prescription eye drops (Travatan Z, Alcon Laboratories) as first-line treatment of elevated IOP associated with open-angle glaucoma or ocular hypertension.

“The FDA approval for first-line use of [travoprost] solution will allow eye-care professionals to start [treating patients with] newly diagnosed glaucoma and ocular hypertension . . . with a product that is already well-received in the marketplace because of its efficacy and safety,” said Stuart Raetzman, Alcon’s vice president of global marketing and area president for the United States. “This approval also means that [travoprost] will be the first and only prostaglandin analogue approved by the FDA for first-line treatment of glaucoma patients that does not contain the preservative benzalkonium chloride.”

The company developed travoprost with a proprietary ionic-buffered preservative system (sofZia). The ophthalmic solution was introduced in the United States in 2006.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
© 2025 MJH Life Sciences

All rights reserved.